A total of 182 randomly assigned patients died or had progression to ESRD (60 patients in the monotherapy group and 63 patients in the combination- therapy group died), and 143 exited the study before it was closed (66 withdrew, 39 were lost to follow-up, 26 were at study sites that stopped participating in the study, and 12 had
other reasons).